Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma

Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma

Introduction: Dysregulated MET signaling, such as MET overexpression or MET amplification (METamp), is a important mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant lung adenocarcinoma (LUAD). Combination therapy with EGFR TKIs and MET TKIs has revealed e...

Full description

Saved in:
Bibliographic Details
Main Authors: Jia-Jun Wu, MD, Zhe-Rong Zheng, MD, Tse-Hsien Lo, MD, Cheng-Hsiang Chu, MD, Kun-Chieh Chen, MD, PhD, Gee-Chen Chang, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:JTO Clinical and Research Reports
Subjects:
EGFR mutation
EGFR tyrosine kinase inhibitor
Lung adenocarcinoma (LUAD)
MET overexpression
MET tyrosine kinase inhibitor
Non–small cell lung cancer (NSCLC)
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364325000487
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666364325000487

Similar Items